Background. Since circulating tumor DNA (ctDNA) offers clear advantages as a minimally invasive method for tumor monitoring\ncompared with tumor tissue, we aimed to evaluate genotyping ctDNA using a next-generation sequencing- (NGS-) based panel\nto identify the prognostic value of mutation status in metastatic colorectal cancer (mCRC) patients with primary tumor resected\nand with subsequent lines of treatment in this study. Methods. 76 mCRC patients treated in Beijing Chao-Yang Hospital from 2011\nto 2017 were enrolled. Genotyping of RAS/BRAF in tumor tissue and ctDNA was determined by ARMS PCR and with a 40-gene\npanel using NGS, respectively. Patient clinicopathologic features and RAS/BRAF gene mutation status were evaluated by survival\nanalysis for disease-free survival (DFS) and progression-free survival (PFS). Results. Among 76 patients, KRAS distributions were\nnot significantly correlated with any clinicopathologic features.Theconcordance between tumor tissue and ctDNAKRASmutation\nwas 81.25%. Mutations of RAS/BRAF had no significant impact on DFS after surgery (hazard ratio (HR), 1.205; 95% CI, 0.618 to\n2.349;
Loading....